• Je něco špatně v tomto záznamu ?

European Association of Urology Guidelines on the Diagnosis and Treatment of Urolithiasis

A. Skolarikos, R. Geraghty, B. Somani, T. Tailly, H. Jung, A. Neisius, A. Petřík, GM. Kamphuis, N. Davis, C. Bezuidenhout, M. Lardas, G. Gambaro, JA. Sayer, R. Lombardo, L. Tzelves

. 2025 ; 88 (1) : 64-75. [pub] 20250422

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, směrnice pro lékařskou praxi

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015197

BACKGROUND AND OBJECTIVE: The European Association of Urology urolithiasis guidelines provide evidence-based recommendations for the diagnosis and treatment of urinary stone disease. Given the complexity and variability of stone formation, individualised patient management is emphasised. METHODS: The guidelines incorporate evidence from the latest research and focus on risk assessment, imaging techniques, pharmacological management, and surgical interventions. A research librarian conducted literature searches for urolithiasis in the Cochrane Library, Medline, and Embase databases via Dialog-Datastar. The strength of recommendations is also rated. KEY FINDINGS AND LIMITATIONS: Diagnosis relies on a combination of clinical history, biochemical evaluation, and imaging, with ultrasound as the first-line modality and low-dose computed tomography as the gold standard for precise stone assessment. Stone composition and burden influence treatment decisions with algorithms primarily based on stone size, location, and composition. Nonsteroidal anti-inflammatory drugs are recommended for first-line pain management, with opioids reserved as a secondary option. Medical expulsive therapy with α-blockers may be considered for selected patients with ureteral stones. Extracorporeal shockwave lithotripsy, ureteroscopy, and percutaneous nephrolithotomy remain the primary intervention modalities, with selection based on stone characteristics and patient factors. Advances in multiplanar imaging have improved assessment of the stone burden, although further research is needed to refine predictive models. Genetic testing is recommended for high-risk patients to guide personalised treatment. CONCLUSIONS AND CLINICAL IMPLICATIONS: The guidelines provide a framework for clinical decision-making while acknowledging the need for continued advances in urolithiasis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015197
003      
CZ-PrNML
005      
20250731090826.0
007      
ta
008      
250708s2025 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.eururo.2025.03.011 $2 doi
035    __
$a (PubMed)40268592
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Skolarikos, Andreas $u 2nd Department of Urology, National and Kapodistrian University of Athens, Sismanogleio Hospital, Athens, Greece. Electronic address: andskol@yahoo.com
245    10
$a European Association of Urology Guidelines on the Diagnosis and Treatment of Urolithiasis / $c A. Skolarikos, R. Geraghty, B. Somani, T. Tailly, H. Jung, A. Neisius, A. Petřík, GM. Kamphuis, N. Davis, C. Bezuidenhout, M. Lardas, G. Gambaro, JA. Sayer, R. Lombardo, L. Tzelves
520    9_
$a BACKGROUND AND OBJECTIVE: The European Association of Urology urolithiasis guidelines provide evidence-based recommendations for the diagnosis and treatment of urinary stone disease. Given the complexity and variability of stone formation, individualised patient management is emphasised. METHODS: The guidelines incorporate evidence from the latest research and focus on risk assessment, imaging techniques, pharmacological management, and surgical interventions. A research librarian conducted literature searches for urolithiasis in the Cochrane Library, Medline, and Embase databases via Dialog-Datastar. The strength of recommendations is also rated. KEY FINDINGS AND LIMITATIONS: Diagnosis relies on a combination of clinical history, biochemical evaluation, and imaging, with ultrasound as the first-line modality and low-dose computed tomography as the gold standard for precise stone assessment. Stone composition and burden influence treatment decisions with algorithms primarily based on stone size, location, and composition. Nonsteroidal anti-inflammatory drugs are recommended for first-line pain management, with opioids reserved as a secondary option. Medical expulsive therapy with α-blockers may be considered for selected patients with ureteral stones. Extracorporeal shockwave lithotripsy, ureteroscopy, and percutaneous nephrolithotomy remain the primary intervention modalities, with selection based on stone characteristics and patient factors. Advances in multiplanar imaging have improved assessment of the stone burden, although further research is needed to refine predictive models. Genetic testing is recommended for high-risk patients to guide personalised treatment. CONCLUSIONS AND CLINICAL IMPLICATIONS: The guidelines provide a framework for clinical decision-making while acknowledging the need for continued advances in urolithiasis.
650    _2
$a lidé $7 D006801
650    _2
$a litotripse $x normy $7 D008096
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a společnosti lékařské $7 D012955
650    _2
$a ureteroskopie $x normy $7 D018666
650    12
$a urolitiáza $x terapie $x diagnóza $7 D052878
650    12
$a urologie $x normy $7 D014572
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a směrnice pro lékařskou praxi $7 D017065
700    1_
$a Geraghty, Robert $u Department of Urology, Freeman Hospital, Newcastle upon Tyne, UK
700    1_
$a Somani, Bhaskar $u Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK
700    1_
$a Tailly, Thomas $u Servicio de Urología, Hospital Universitario de Gante, Gante, Belgium
700    1_
$a Jung, Helene $u Urinvejskirurgisk Afdeling, Sygehus Lillebælt, Vejle, Denmark
700    1_
$a Neisius, Andreas $u Department of Urology, Hospital of the Brothers of Mercy Trier, Medical Campus University Mainz, Trier, Germany
700    1_
$a Petřík, Ales $u Department of Urology, Region Hospital, Ceske Budejovice, Czechia
700    1_
$a Kamphuis, Guido M $u Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
700    1_
$a Davis, Niall $u Department of Urology, Connolly Hospital, Dublin, Ireland
700    1_
$a Bezuidenhout, Carla $u European Association of Urology, Arnhem, The Netherlands
700    1_
$a Lardas, Michael $u 2nd Department of Urology, National and Kapodistrian University of Athens, Sismanogleio Hospital, Athens, Greece
700    1_
$a Gambaro, Giovanni $u Division of Nephrology and Dialysis, Department of Medicine, University of Verona, Verona, Italy
700    1_
$a Sayer, John A $u Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK; Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
700    1_
$a Lombardo, Riccardo $u Sant'Andrea Hospital, Sapienza University, Rome, Italy
700    1_
$a Tzelves, Lazaros $u 2nd Department of Urology, National and Kapodistrian University of Athens, Sismanogleio Hospital, Athens, Greece
773    0_
$w MED00001669 $t European urology $x 1873-7560 $g Roč. 88, č. 1 (2025), s. 64-75
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40268592 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090821 $b ABA008
999    __
$a ok $b bmc $g 2366197 $s 1252322
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 88 $c 1 $d 64-75 $e 20250422 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace